? Chief Business Officer to Provide Business and Development
Program Updates ?
DUBLIN, Ohio--(BUSINESS WIRE)--
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents, today announced that Dr.
Thomas Tulip, Executive Vice President and Chief Business Officer, will
participate at the Jeffries 2012 Global Healthcare Conference on June
4-7 at the Grand Hyatt in New York City. Dr. Tulip will provide an
update of the Company and its development programs on Wednesday, June 6,
2012 at 4:30 PM EDT.
Investors and the public are invited to listen to a live webcast of Dr.
Tulip's presentation at http://wsw.com/webcast/jeff68/navb/.
Following the conference, the webcast will be archived for approximately
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is actively developing three radiopharmaceutical agent
platforms ? Lymphoseek®, AZD4694 and RIGScanTM ?
to help identify the sites and pathways of undetected disease and enable
better diagnostic accuracy, clinical decision-making and ultimately
patient care. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company's pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.